W. Symonds

发表

Sofosbuvir for previously untreated chronic hepatitis C infection.

John McNally, Michael Schultz, A. Mangia, 2013, The New England journal of medicine.

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Robert Herring, Vinod Rustgi, E. Schiff, 2014, The New England journal of medicine.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Stefan Zeuzem, Norman Gitlin, M. Buti, 2014, The New England journal of medicine.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Sanjeev Arora, Norman Gitlin, Robert Herring, 2014, The New England journal of medicine.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Brad J. Wood, M. Proschan, A. Fauci, 2015, The Lancet.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

C. Stedman, E. Gane, E. Svarovskaia, 2013, The New England journal of medicine.

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

T. Hassanein, K. Kowdley, D. Bernstein, 2013, The Lancet.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

E. Schiff, G. Everson, K. Kowdley, 2013, The New England journal of medicine.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

K. Reddy, T. Hassanein, D. Dieterich, 2013, The Lancet. Infectious diseases.

1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?

D. Bernstein, T. Hassanein, D. Nelson, 2012 .

1113 ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3

C. Stedman, E. Gane, R. Hindes, 2012 .

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males

B. Sadler, D. Brophy, R. Polk, 2001, Antimicrobial Agents and Chemotherapy.

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

A. Lok, K. Reddy, T. Hassanein, 2014, The New England journal of medicine.

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2014, The Lancet.

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Brad J. Wood, M. Proschan, R. Dewar, 2013, JAMA.

Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.

S. Mikhail, B. Doehle, P. Ruane, 2015, Journal of hepatology.

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

H. Dvory‐Sobol, D. Brainard, J. McHutchison, 2015, Hepatology.

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

P. Marcellin, A. Mangia, K. Reddy, 2015, Hepatology.

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

R. Fontana, X. Forns, T. Baumert, 2015, Hepatology.

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

A. Mathias, B. Kearney, B. Kirby, 2015, Clinical Pharmacokinetics.

Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV

J. Rodríguez-Orengo, A. Gaggar, D. Brainard, 2015, Journal of acquired immune deficiency syndromes.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

H. Mo, P. Pang, J. McHutchison, 2014, The Lancet.

Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection

E. Lawitz, W. Symonds, E. Albanis, 2012, Antimicrobial Agents and Chemotherapy.

svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2013 .

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

K. Reddy, E. Gane, D. Brainard, 2015, Hepatology.

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

V. de Lédinghen, P. Marcellin, F. Zoulim, 2015, The Lancet. Infectious diseases.

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

T. Ide, N. Izumi, H. Mo, 2015, The Lancet. Infectious diseases.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

C. Stedman, P. Pang, E. Gane, 2014, Gastroenterology.

Development of sofosbuvir for the treatment of hepatitis C virus infection

D. Dieterich, S. Zeuzem, D. Nelson, 2015, Annals of the New York Academy of Sciences.

Méthodes de traitement du virus de l'hépatite c

P. Pang, R. Hyland, W. Symonds, 2014 .

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed

T. Hassanein, H. Mo, S. Pol, 2015, Hepatology.

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.

M. Manns, R. Fontana, X. Forns, 2015, Gastroenterology.

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

N. Parkin, H. Mo, V. Gontcharova, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial

T. Ide, N. Izumi, O. Yokosuka, 2014, Journal of viral hepatitis.

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

K. Mounzer, D. Dieterich, D. Asmuth, 2014, JAMA.

O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY

T. Asselah, X. Forns, G. Everson, 2014 .

O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE

C. Stedman, P. Pang, E. Gane, 2014 .

sofosbuvir in Combination With Pegifn and Ribavirin for 12 Weeks Provides High Svr Rates in Hcv-infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the Lonestar-2 Study : lb-4

D. Brainard, J. McHutchison, E. Lawitz, 2013 .

O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2)

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2014 .

O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS

Z. Younossi, S. Ouwerkerk-Mahadevan, M. Sulkowski, 2014 .

Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men

A. Pastor, B. Sadler, M. Crouch, 1999, Pharmacotherapy.

Risk factor analysis of hypersensitivity reactions to abacavir.

S. Hetherington, W. Symonds, A. Cutrell, 2002, Clinical therapeutics.

Single-Dose Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor, in HIV-Infected Children

R. Yogev, A. Kovacs, E. Chadwick, 2005, Antimicrobial Agents and Chemotherapy.

Regulation of peroxisome proliferator-activated receptor- (cid:1) in liver ﬁbrosis

D. Rockey, Che-chang Chan, Liu Yang, 2006 .

Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers

A. Pastor, B. Sadler, D. Brophy, 2000, Antimicrobial Agents and Chemotherapy.

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.

K. Kowdley, D. Nelson, J. McHutchison, 2013, Journal of hepatology.

1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977

T. Marbury, W. Symonds, M. Sale, 2012 .

Focus on itraconazole: A broad-spectrum antifungal agent for treatment of blastomycosis and histoplasmosis

W. Symonds, D. Nix, G. O'Connor, 1993 .

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Riina Salupere, Stefan Zeuzem, Robert Flisiak, 2014, The New England journal of medicine.

1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA

E. Lawitz, W. Symonds, M. Berrey, 2011 .

66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS

G. Everson, D. Nelson, E. Gane, 2008 .

37 SUSTAINED VIROLOGIC RESPONSE (SVR) FOLLOWING RG7128 1500MG BID/PEG-IFN/RBV FOR 28 DAYS IN HCV GENOTYPE 2/3 PRIOR NON-RESPONDERS

E. Gane, J. McHutchison, I. Jacobson, 2010 .

61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

T. Hassanein, D. Nelson, E. Lawitz, 2011 .

Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938

Jeremie Guedj, Alan S Perelson, William Symonds, 2014, Antiviral therapy.

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults

B. Sadler, W. Symonds, N. Roskell, 1999, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects

W. Symonds, M. Berrey, Stephen Flach, 2012, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System

J. Bilello, G. Drusano, W. Symonds, 2002, Antimicrobial Agents and Chemotherapy.

All‐oral therapy with nucleotide inhibitors sofosbuvir and GS‐0938 for 14 days in treatment‐naive genotype 1 hepatitis C (NUCLEAR)

H. Mo, A. Mathias, E. Lawitz, 2013, Journal of viral hepatitis.

1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

D. Bernstein, T. Hassanein, D. Dieterich, 2011 .

Assessment of the Enzymuria Resulting from Gentamicin Alone and Combinations of Gentamicin with Various β-Lactam Antibiotics

Jerome J. Schentag, W. Symonds, J. Wilton, 1997, The Annals of pharmacotherapy.

Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis.

D. Rockey, Che-chang Chan, Liu Yang, 2006, American journal of physiology. Gastrointestinal and liver physiology.

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

E. Schiff, X. Forns, R. Chung, 2015, Gastroenterology.

Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir

J. Bilello, G. Drusano, M. Rogers, 2000, Antimicrobial Agents and Chemotherapy.

Comparative Pharmacokinetics of Oral Ceftibuten, Cefixime, Cefaclor, and Cefuroxime Axetil in Healthy Volunteers

M. Affrime, W. Symonds, J. Wilton, 1997, Pharmacotherapy.

1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY

K. Reddy, K. Kowdley, Z. Younossi, 2013 .

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

K. Kowdley, D. Nelson, D. Brainard, 2013 .

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL

H. Mo, K. Kowdley, D. Nelson, 2013 .

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY

C. Stedman, P. Pang, E. Gane, 2013 .

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

A. Lok, K. Reddy, T. Hassanein, 2013 .

P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY

M. Manns, R. Fontana, X. Forns, 2014 .

O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION

R. Fontana, X. Forns, T. Baumert, 2014 .

Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders

Z. Younossi, I. Jacobson, E. Lawitz, 2013 .

5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION)

A. Mangia, E. Gane, H. Dvory‐Sobol, 2013 .

238 Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in HCV Infected Populations Including Decompensated Patients and Patients With Prior Sofosbuvir Treatment Experience

C. Stedman, P. Pang, E. Gane, 2014 .

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

R. Chung, G. Everson, B. Doehle, 2014 .

1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS

E. Lawitz, W. Symonds, L. Fang, 2012 .

Regulation of peroxisome proliferator-activated receptor- in liver fibrosis

D. Rockey, Che-chang Chan, Liu Yang, 2006 .

1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS

Sanjeev Arora, T. Hassanein, D. Nelson, 2012 .

O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY

S. Zeuzem, B. Doehle, D. Brainard, 2014 .

Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection

P. Cutler, D. Rockey, A. Zekry, 2007, Journal of Translational Medicine.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects

W. Symonds, J. Borland, I. Song, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours

J. Bilello, G. Drusano, W. Symonds, 2003, Antimicrobial Agents and Chemotherapy.

845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY

D. Nelson, E. Lawitz, R. Hyland, 2013 .

Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro

J. Bilello, G. Drusano, B. Sadler, 1998, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeﬁciency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects (cid:1)

W. Symonds, J. Borland, I. Song, 2007 .

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

R. Fontana, H. Appelman, R. Hindes, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

O55 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR OF HCV GENOTYPE-1 INFECTED PATIENTS WHO FAILED PRIOR THERAPY WITH PEGINTERFERON + RIBAVIRIN PLUS 1 OR 2 ADDITIONAL DIRECT-ACTING ANTIVIRAL AGENTS

T. Hassanein, S. Pol, E. Gane, 2014 .

P1243 SOFOSBUVIR PLUS RIBAVIRIN, AN INTERFERON-FREE REGIMEN, IN THE TREATMENT OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC GENOTYPE 4 HCV INFECTION

S. Mikhail, B. Doehle, P. Ruane, 2014 .

O66 SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS

B. Conway, S. Zeuzem, G. Foster, 2014 .

All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study

T. Berg, G. Gerken, P. Pang, 2014 .

Chronic Hepatitis C Infection Multiple Ascending Doses in Patients with Analog Polymerase Inhibitor, following Tolerability of GS-9851, a Nucleotide Pharmacokinetics, Pharmacodynamics, and

E. Lawitz, W. Symonds, M. Berrey, 2014 .

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

H. Mo, P. Pang, J. McHutchison, 2014, The Lancet.

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

P. Thuluvath, D. Grasela, M. Sulkowski, 2014, The New England journal of medicine.

848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR

T. Hassanein, K. Kowdley, E. Gane, 2013 .

7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3

C. Stedman, K. Reddy, T. Hassanein, 2012 .

O14 USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV

M. Polis, H. Masur, R. Talwani, 2014 .

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

K. Reddy, E. Gane, D. Brainard, 2015, Hepatology.

LB-1 Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection

Z. Younossi, S. Ouwerkerk-Mahadevan, M. Sulkowski, 2013 .

P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS

A. Mangia, D. Nelson, E. Gane, 2014 .

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase

J. Pawlotsky, A. Zekry, K. Patel, 2008, Journal of viral hepatitis.

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.

K. Kowdley, D. Nelson, E. Lawitz, 2013, Journal of hepatology.